GlassScriptPhysician profile
Celeste M Thornton
NPI 1033131404
$781.86
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $770 · 2022: $12.08.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $170.43 | 2021 | |
| Novo Nordisk INC | $164.73 | 2021 | |
| Lilly USA, LLC | $114.29 | 2021 | |
| Abbvie INC. | $69.26 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.87 | 2021 | |
| Amarin Pharma, INC. | $45.32 | 2021 | |
| Abbott Laboratories | $34.31 | 2021 | |
| Merck Sharp & Dohme LLC | $31.45 | 2021 | |
| Eisai INC. | $29.79 | 2021 | |
| Janssen Pharmaceuticals, INC | $19.29 | 2021 | |
| Sunovion Pharmaceuticals INC. | $17.34 | 2021 | |
| Esperion Therapeutics, INC. | $15.40 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.00 | 2021 | |
| Lupin INC. | $11.38 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Celeste Thornton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.